Astra uncertainty

Shares at Anglo-Swedish pharmaceutical group AstraZeneca are down more than 6 per cent after chief executive David Brennan announced he plans to step down early. Investor frustration has been brewing as the stock has fallen during the recent market recovery. Lex's Richard Stovin-Bradford and Nikki Tait discuss the difficulties a new chief faces turning the company around.